174 related articles for article (PubMed ID: 35681672)
1. Combination of OX40 Co-Stimulation, Radiotherapy, and PD-1 Inhibition in a Syngeneic Murine Triple-Negative Breast Cancer Model.
Han MG; Wee CW; Kang MH; Kim MJ; Jeon SH; Kim IA
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681672
[TBL] [Abstract][Full Text] [Related]
2. PI3Kαδ Inhibitor Combined With Radiation Enhances the Antitumor Immune Effect of Anti-PD1 in a Syngeneic Murine Triple-Negative Breast Cancer Model.
Chang WI; Han MG; Kang MH; Park JM; Kim EE; Bae J; Ahn S; Kim IA
Int J Radiat Oncol Biol Phys; 2021 Jul; 110(3):845-858. PubMed ID: 33642128
[TBL] [Abstract][Full Text] [Related]
3. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
Han MG; Jang BS; Kang MH; Na D; Kim IA
Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
[TBL] [Abstract][Full Text] [Related]
4. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
[TBL] [Abstract][Full Text] [Related]
5. Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.
Niknam S; Barsoumian HB; Schoenhals JE; Jackson HL; Yanamandra N; Caetano MS; Li A; Younes AI; Cadena A; Cushman TR; Chang JY; Nguyen QN; Gomez DR; Diab A; Heymach JV; Hwu P; Cortez MA; Welsh JW
Clin Cancer Res; 2018 Nov; 24(22):5735-5743. PubMed ID: 29784675
[No Abstract] [Full Text] [Related]
6. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
7. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
Jahan N; Talat H; Curry WT
Neuro Oncol; 2018 Jan; 20(1):44-54. PubMed ID: 29016879
[TBL] [Abstract][Full Text] [Related]
8. Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma.
Jahan N; Talat H; Alonso A; Saha D; Curry WT
Oncoimmunology; 2019; 8(5):e1577108. PubMed ID: 31069135
[TBL] [Abstract][Full Text] [Related]
9. Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve.
Fabian KP; Padget MR; Fujii R; Schlom J; Hodge JW
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602696
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
11. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
Gao M; Wang T; Ji L; Bai S; Tian L; Song H
Front Immunol; 2020; 11():366. PubMed ID: 32194569
[TBL] [Abstract][Full Text] [Related]
12. Abscopal Effect of Radiotherapy Enhanced with Immune Checkpoint Inhibitors of Triple Negative Breast Cancer in 4T1 Mammary Carcinoma Model.
Song HN; Jin H; Kim JH; Ha IB; Kang KM; Choi HS; Jeong HJ; Kim MY; Kim HJ; Jeong BK
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638817
[TBL] [Abstract][Full Text] [Related]
13. Enhancing the Generation of Eomes
Emerson DA; Rolig AS; Redmond WL
Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
[TBL] [Abstract][Full Text] [Related]
14.
Cai Z; Liu R; Chan C; Lu Y; Winnik MA; Cescon DW; Reilly RM
Mol Pharm; 2022 Nov; 19(11):4199-4211. PubMed ID: 36287201
[TBL] [Abstract][Full Text] [Related]
15. OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection.
Jacobi FJ; Wild K; Smits M; Zoldan K; Csernalabics B; Flecken T; Lang J; Ehrenmann P; Emmerich F; Hofmann M; Thimme R; Neumann-Haefelin C; Boettler T
J Hepatol; 2019 Jun; 70(6):1103-1113. PubMed ID: 30826436
[TBL] [Abstract][Full Text] [Related]
16. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis.
Garrison K; Hahn T; Lee WC; Ling LE; Weinberg AD; Akporiaye ET
Cancer Immunol Immunother; 2012 Apr; 61(4):511-21. PubMed ID: 21971588
[TBL] [Abstract][Full Text] [Related]
17. Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.
Pilones KA; Hensler M; Daviaud C; Kraynak J; Fucikova J; Galluzzi L; Demaria S; Formenti SC
Oncoimmunology; 2020 Oct; 9(1):1830524. PubMed ID: 33150045
[TBL] [Abstract][Full Text] [Related]
18. OX40 enhances T cell immune response to PD-1 blockade therapy in non-small cell lung cancer.
Lao J; Cao C; Niu X; Deng S; Ming S; Liang S; Shang Y; Yuan Y; Shi X; Liang Z; Wu M; Wu Y
Int Immunopharmacol; 2022 Jul; 108():108813. PubMed ID: 35580452
[TBL] [Abstract][Full Text] [Related]
19. Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response.
Rupp T; Genest L; Babin D; Legrand C; Hunault M; Froget G; Castagné V
Transl Oncol; 2022 Jun; 20():101405. PubMed ID: 35339889
[TBL] [Abstract][Full Text] [Related]
20. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
